| First Author | Malumbres M | Year | 2016 |
| Journal | Cancer Cell | Volume | 29 |
| Issue | 3 | Pages | 243-4 |
| PubMed ID | 26977873 | Mgi Jnum | J:231768 |
| Mgi Id | MGI:5774906 | Doi | 10.1016/j.ccell.2016.02.016 |
| Citation | Malumbres M (2016) CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2(+) Breast Cancer. Cancer Cell 29(3):243-4 |
| abstractText | CDK4/6 inhibitors have received approval for treating hormone-positive breast tumors, but whether other aggressive cancers respond to these molecules is not yet clear. In this issue of Cancer Cell, Goel et al. (2016) report an unexpected activity of CDK4/6 inhibitors in reducing mTOR function and re-sensitizing HER2-positive cancers to EGFR/HER2 blockade. |
